Replimune Group, Inc. (REPL)

NASDAQ: REPL · IEX Real-Time Price · USD
8.85
-0.01 (-0.11%)
Feb 28, 2024, 1:44 PM EST - Market open
-0.11%
Market Cap 528.55M
Revenue (ttm) n/a
Net Income (ttm) -209.96M
Shares Out 61.39M
EPS (ttm) -3.16
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 387,904
Open 8.76
Previous Close 8.86
Day's Range 8.74 - 9.09
52-Week Range 5.89 - 24.81
Beta 1.23
Analysts Strong Buy
Price Target 44.50 (+402.83%)
Earnings Date Feb 8, 2024

About REPL

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutan... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 20, 2018
Employees 284
Stock Exchange NASDAQ
Ticker Symbol REPL
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 6 analysts, the average rating for REPL stock is "Strong Buy." The 12-month stock price forecast is $44.5, which is an increase of 402.83% from the latest price.

Price Target
$44.5
(402.83% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Replimune Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update

WOBURN, Mass., Feb. 08, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, ...

20 days ago - GlobeNewsWire

Replimune to Present at the 42nd Annual J.P. Morgan Healthcare Conference

WOBURN, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of oncolytic immunotherapies, ...

2 months ago - GlobeNewsWire

Replimune shares plunge as skin cancer therapy fails to meet primary clinical-trial goals

Replimune Group Inc. shares REPL, +5.21% dropped more than 40% premarket on Tuesday after the biotech company said an investigational cancer therapy had failed to meet its primary goals in a clinical ...

3 months ago - Market Watch

Replimune Shares Initial Primary Analysis Results from CERPASS Clinical Trial in Advanced Cutaneous Squamous Cell Carcinoma and Presents New Data from IGNYTE Clinical Trial of RP1 in Anti-PD1 Failed Melanoma and Non-Melanoma Skin Cancers

RP1 in combination with cemiplimab demonstrated clinically meaningful improvements in complete response rate and duration of response compared to cemiplimab in the CERPASS clinical trial, but did not ...

3 months ago - GlobeNewsWire

Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research

RP2 as monotherapy and in combination with nivolumab showed a favorable safety profile and durable responses in nearly 30 percent of patients, all with previously treated disease RP2 as monotherapy an...

4 months ago - GlobeNewsWire

Replimune Reports Fiscal Second Quarter 2024 Financial Results and Provides Corporate Update

The Company plans to hold a conference call in early December to provide a comprehensive RP1 skin cancer program update including:

4 months ago - GlobeNewsWire

Replimune Presents Updated Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers During Oral Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

RP1 as monotherapy showed clear anti-tumor activity with an overall response rate of nearly 35 percent in evaluable patients RP1 as monotherapy showed clear anti-tumor activity with an overall respons...

4 months ago - GlobeNewsWire

Tessellate BIO Emerges from Stealth

The company aims to become a global leader in precision oncology by redefining Synthetic Lethality to treat large, currently unserved patient populations Lead program targets Alternative Lengthening o...

Other symbols: NAMS
4 months ago - GlobeNewsWire

Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WOBURN, Mass., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherap...

5 months ago - GlobeNewsWire

Replimune Reports Fiscal First Quarter 2024 Financial Results and Provides Corporate Update

Topline data from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo ® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma expected in early Q4 2023 and Biologics License...

7 months ago - GlobeNewsWire

Replimune Announces Sander Slootweg will Depart from its Board of Directors

WOBURN, Mass., July 20, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic im...

7 months ago - GlobeNewsWire

Replimune Presents Initial RP1 Data from the ARTACUS Clinical Trial at the 2023 American Transplant Congress (ATC) Meeting

Single agent RP1 showed meaningful anti-tumor activity, with an overall response rate of 27.3% (all complete responses) in evaluable patients, with all responses ongoing to date Single agent RP1 showe...

9 months ago - GlobeNewsWire

Replimune Appoints Veleka R. Peeples-Dyer to its Board of Directors

WOBURN, Mass., June 05, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolyti...

9 months ago - GlobeNewsWire

Replimune Presents RP1 Data from the IGNYTE anti-PD1 Failed Melanoma Cohort and RP2 Data in Uveal Melanoma at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

Updated data from ongoing IGNYTE anti-PD1 failed melanoma cohort shows RP1 combined with nivolumab continues to demonstrate deep and durable responses with a well-tolerated safety profile; no progress...

9 months ago - GlobeNewsWire

Replimune to Present at the Jefferies Global Healthcare Conference

WOBURN, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolyti...

9 months ago - GlobeNewsWire

Replimune to Present at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting

WOBURN, Mass., May 25, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic imm...

9 months ago - GlobeNewsWire

Replimune Reports Fiscal Fourth Quarter and Year Ended 2023 Financial Results and Provides Corporate Update

Topline data disclosure from the registration-directed CERPASS clinical trial of RP1 combined with Libtayo ® (cemiplimab-rwlc) in cutaneous squamous cell carcinoma (CSCC) on track for Q3 2023 and Biol...

10 months ago - GlobeNewsWire

Dualyx raises €40 million to progress Treg therapies for autoimmune diseases into the clinic

Dualyx r aises € 40 m illion to progress Treg therapies for autoimmune diseases into the clinic

Other symbols: NAMS
10 months ago - GlobeNewsWire

Replimune to Present at Two Upcoming Investor Conferences

WOBURN, Mass., March 08, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel portfolio of tumor-directed oncolyt...

1 year ago - GlobeNewsWire

Replimune Reports Fiscal Third Quarter Financial Results and Provides Corporate Update

Strengthened balance sheet raising gross $259 million through an upsized public offering in December, extending cash runway into H2 2025 and increasing operational and strategic flexibility

1 year ago - GlobeNewsWire

Replimune to Present at the 41st Annual J.P. Morgan Healthcare Conference

WOBURN, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic im...

1 year ago - GlobeNewsWire

Replimune Announces Pricing of Public Offering

BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunothe...

1 year ago - GlobeNewsWire

Replimune Announces Proposed Public Offering

BOSTON, Dec. 07, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunothe...

1 year ago - GlobeNewsWire

Replimune Announces Positive Initial Data from the Anti-PD1 Failed Melanoma Cohort of the IGNYTE Clinical Trial & an RP2/3 Program Update

RP1 combined with nivolumab continues to demonstrate deep and durable responses in patients with anti-PD1 failed melanoma

1 year ago - GlobeNewsWire

Replimune Enters into Clinical Collaboration Agreement with Roche for the Development of RP3 In Colorectal Cancer and Hepatocellular Carcinoma

RP3 will be developed in combination with atezolizumab and bevacizumab for the third-line treatment of colorectal cancer (CRC) and for the first- and second-line treatment of hepatocellular carcinoma ...

1 year ago - GlobeNewsWire